StockNews.com Initiates Coverage on Trevena (NASDAQ:TRVN)

Equities research analysts at StockNews.com initiated coverage on shares of Trevena (NASDAQ:TRVN) in a research report issued on Sunday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Trevena Stock Down 5.1 %

Shares of NASDAQ TRVN opened at $1.12 on Friday. Trevena has a 12-month low of $0.95 and a 12-month high of $11.25. The firm’s 50-day simple moving average is $1.42 and its 200 day simple moving average is $1.68. The company has a market cap of $967,680.00, a price-to-earnings ratio of -0.02 and a beta of 1.10.

Trevena Company Profile

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.